Adrenomedullin (ADM): Molecular Features, Signaling Mechanisms, and Research and Translational Applications of a Multisystem Vasoactive Peptide
Adrenomedullin (ADM): Molecular Features, Signaling Mechanisms, and Research and Translational Applications of a Multisystem Vasoactive Peptide
Adrenomedullin (adrenomedullin, ADM) is an endogenous peptide with potent vasoactive and cytoprotective properties, first isolated and identified from human pheochromocytoma tissue. ADM is broadly expressed in vascular endothelial cells, vascular smooth muscle cells, cardiomyocytes, kidney and lung tissues, and in multiple immune-cell and tumor-associated cell types. Its primary receptor system is a heteromeric complex composed of the calcitonin receptor-like receptor (calcitonin receptor-like receptor, CLR) and receptor activity-modifying proteins (receptor activity-modifying proteins, RAMP2 or RAMP3). This complex mediates signaling networks dominated by cAMP/PKA and integrated with NO, PI3K/AKT, ERK/MAPK, and related pathways. ADM has important physiological roles in vasodilation, endothelial barrier stabilization, anti-inflammatory and anti-apoptotic responses, maintenance of microcirculatory perfusion, and organ protection. In disease states, ADM and its stable fragments (e.g., MR-proADM) reflect the degree of endothelial stress and circulatory dysregulation, and have therefore been widely studied as biomarkers and potential intervention targets in sepsis, heart failure, pulmonary arterial hypertension, renal dysfunction, and related contexts.
Keywords: adrenomedullin; ADM; MR-proADM; CLR; RAMP2; RAMP3; endothelial barrier; microcirculation; vasodilation; cAMP; NO; sepsis; heart failure; pulmonary arterial hypertension; biomarker
I. Molecular Origin and Biosynthesis
1.1 Discovery Context and Tissue Distribution
(1) Discovery and naming
ADM was originally identified in pheochromocytoma tissue and named for its prominent vasodilatory activity.
(2) Expression distribution
ADM is widely expressed in endothelial and smooth muscle compartments and is detectable in highly perfused organs such as the heart, kidney, and lung, as well as in immune-related cells, indicating systemic regulatory roles rather than a strictly “adrenal medulla”-restricted function.
1.2 Precursor Processing and Generation of the Mature Peptide
(1) Precursor protein and processing steps
ADM is produced through proteolytic processing of a precursor protein; formation of the mature peptide involves proteolysis and post-translational modifications, contributing to the complexity of circulating ADM-related molecular species.
(2) Generation and significance of MR-proADM
Compared with mature ADM, MR-proADM is a more stable fragment derived from shared precursor processing. Because it is more stable ex vivo, MR-proADM is commonly used in clinical research as a surrogate indicator of ADM-system activation, reducing the impact of sample-handling uncertainty on quantification.
II. Receptor Complexes and Signal-Transduction Mechanisms
2.1 The CLR–RAMP Receptor System
(1) Receptor composition
ADM signaling is primarily mediated by receptor complexes formed by CLR with RAMP2 or RAMP3. Distinct RAMP pairings can modulate ligand affinity, receptor conformation, and downstream signaling bias.
(2) Receptor distribution and cell-type specificity
Differences in CLR/RAMP expression combinations across endothelium, smooth muscle, and cardiomyocytes determine tissue-specific response magnitude and the spectrum of ADM effects.
2.2 Canonical and Non-Canonical Signaling Axes
(1) cAMP/PKA central axis
Upon receptor activation, ADM commonly signals through Gs to stimulate adenylyl cyclase, increase cAMP, and activate PKA, thereby modulating vascular tone, barrier function, and transcriptional programs.
(2) Coupling to NO and endothelial function
ADM can couple to the eNOS/NO pathway, promoting NO production and contributing to vasodilation and microcirculatory regulation; this contribution is typically greater when endothelial function is preserved.
(3) PI3K/AKT and ERK/MAPK
ADM can activate PI3K/AKT and ERK/MAPK signaling to support cell survival, anti-apoptosis, and repair programs; under stress and inflammatory conditions, these “protective signals” can be important for organ protection.
(4) Internalization and signal duration
Internalization and recycling of the CLR–RAMP complex modulate signaling persistence. Under high ADM exposure or inflammatory states, receptor kinetics may shift and thereby alter effect magnitude.
III. Physiological Functions: A Continuous Logic from Vessels to Barriers to Organ Protection
3.1 Vasodilation and Microcirculatory Perfusion
(1) Regulation of vascular tone
ADM exerts vasodilatory effects that reduce peripheral resistance and can improve microcirculatory perfusion, supporting tissue oxygen delivery under stress.
(2) Regional heterogeneity
Responses to ADM differ across organs and vascular beds; receptor-expression profiles, local NO bioavailability, and inflammatory-mediator backgrounds shape effect size and directionality.
3.2 Endothelial Barrier Stabilization and Anti-Leakage Effects
(1) Mechanistic essentials of barrier stabilization
ADM can strengthen endothelial junctions and reduce inflammation-induced increases in permeability, providing barrier protection under capillary leak-prone states.
(2) Antagonistic modulation of inflammatory mediators
During barrier disruption driven by inflammatory mediators such as TNF-α and IL-1β, ADM-related signaling may counter-regulate permeability, manifesting as reduced leakage and decreased edema risk.
3.3 Anti-Inflammatory Effects and Immune Modulation
(1) Regulation in innate immune contexts
ADM can modulate inflammatory intensity in macrophages, monocytes, and endothelial cells, reshaping cytokine profiles and adhesion-molecule expression and thereby influencing immune-cell recruitment and tissue damage.
(2) Immune–vascular coupling
ADM sits at a key position in coupled loops linking immune activation, endothelial stress, and microcirculatory imbalance, making it both a readout of disease progression and a potential intervention node.
3.4 Organ-Protective Effects in Heart, Kidney, Lung, and Beyond
(1) Cardiovascular system
In heart failure or volume-overload states, ADM is linked to vasodilation, natriuresis/diuresis, and cardiomyocyte-protective mechanisms.
(2) Renal system
ADM is associated with renal blood flow, the glomerular filtration environment, and tubular stress responses, and is often studied as an integrated indicator of circulatory and renal functional imbalance.
(3) Pulmonary circulation and pulmonary arterial hypertension
ADM has regulatory actions in the pulmonary vascular bed and is linked to vascular tone and endothelial function in studies of PAH and acute lung injury.
IV. Detection and Characterization: From an Unstable Active Peptide to Usable Biomarkers
4.1 Measurement Strategies for ADM and MR-proADM
(1) Challenges in ADM measurement
Mature ADM exhibits limited ex vivo stability; sample collection, anticoagulant choice, and storage conditions can strongly influence quantitative results.
(2) Advantages of MR-proADM
MR-proADM is more stable and better suited for clinical cohorts and multi-center comparisons, and is commonly used as a surrogate indicator of ADM-system activation.
4.2 Pre-Analytical Variables and Quality Control
(1) Sample types and handling
① Choice of plasma versus serum, anticoagulant type, timing of centrifugation, and storage temperature should be standardized.
② Freeze–thaw cycles and storage duration should be recorded and controlled.
(2) Calibration and inter-batch comparability
① Use the same analytical platform or establish cross-platform calibration to improve longitudinal comparability.
② For multi-center studies, use pooled QC materials to monitor inter-batch drift.
V. Research Applications: Mechanistic Studies, Model Systems, and Pharmacology
5.1 Endothelial Barrier and Microcirculation Models
(1) Endothelial permeability models
① Use TEER, impedance-based assays, or tracer-permeability experiments to quantify barrier function.
② Induce leak with inflammatory cytokines and evaluate ADM modulation of permeability and junctional proteins.
(2) Microcirculatory functional readouts
① Assess vascular tone and perfusion changes in animal or ex vivo vessel systems.
② Combine tissue oxygenation and capillary-perfusion metrics to build multi-layer readouts.
5.2 Sepsis and Systemic Inflammation Research
(1) Readout for disease severity and prognosis
ADM/MR-proADM levels often correlate with circulatory failure and endothelial stress, enabling stratification and mechanistic association analyses.
(2) Pharmacological validation as an intervention target
In animal models, exogenous ADM, receptor blockade, or modulation of the receptor complex can be used to evaluate impacts on leakage, hypoperfusion, and organ injury. The relative contributions of “hemodynamic effects” versus “barrier/immune effects” should be explicitly separated.
5.3 Heart Failure and Cardiovascular Disease Research
(1) Fluid biomarkers and risk stratification
MR-proADM is a candidate indicator reflecting vascular function and circulatory stress and can complement established heart-failure biomarkers.
(2) Mechanisms of cardioprotection and remodeling
Use cardiomyocyte stress models and heart-failure animal models to study ADM effects on anti-apoptosis, anti-fibrosis, or microcirculatory improvement, with receptor-specific interventions used to validate causal links.
5.4 Pulmonary Arterial Hypertension and Acute Lung Injury Research
(1) Pulmonary vascular tone and endothelial function
ADM-mediated vasodilation and barrier protection in the pulmonary vascular bed can be treated as mechanistic variables in PAH and ALI/ARDS studies.
(2) Interactions with hypoxia and inflammation
Hypoxia and inflammation can alter receptor expression and NO bioavailability, reshaping ADM effect spectra; experimental design should fix environmental variables and use controls to decompose contributions.
VI. Translational and Application Prospects: Biomarkers, Stratification, and Targeted Intervention
6.1 Biomarkers and Clinical Stratification
(1) Risk stratification and prognostic evaluation
MR-proADM has been used for risk stratification and prognostic assessment across multiple critical-illness and circulatory disorders, with potential advantages in reflecting endothelial function and microcirculatory imbalance.
(2) Complementarity with multi-marker panels
Combining MR-proADM with inflammation markers, cardiac load markers, or renal-function indices can broaden coverage of the “vascular–barrier–organ injury” chain.
6.2 Therapeutic Development and Dosing-Strategy Challenges
(1) Constraints of direct ADM supplementation
Exogenous ADM can cause hypotension due to vasodilation, limiting its direct therapeutic window in certain critical-care settings.
(2) Receptor-system modulation and “functional separation” concepts
Targeting the CLR–RAMP2/3 receptor system to preserve barrier and organ-protective effects while reducing excessive vasodilation is a central direction in translational development.
VII. Methodological Considerations and Common Pitfalls
7.1 Interpretation Boundaries and Confounders
① Interpreting elevated ADM as simply “increased protection” or attributing it to a single etiology is risky; it more commonly reflects integrated endothelial stress and circulatory imbalance.
② Differences in sample handling and analytical platforms can introduce large systematic biases; cross-study comparisons require caution.
③ Background differences in receptor expression and NO bioavailability can alter effect direction and magnitude and should be constrained with receptor- and pathway-level controls.
7.2 Standardization Recommendations
① Measure ADM and MR-proADM in parallel, or prioritize MR-proADM to improve comparability.
② Build specificity evidence chains using receptor blockade, RAMP2/3 perturbation, and pathway inhibition.
③ Report hemodynamic, barrier, and inflammatory readouts in parallel to avoid extrapolating from single endpoints.
VIII. Aladdin-Related Products
8.1 Adrenomedullin (ADM)-Related Peptides and Isotope-Labeled Peptide Products
Catalog No. | Product Name | Grade and Purity |
adrenomedullin | Moligand™ | |
adrenomedullin | Moligand™ | |
Adrenomedullin (rat) | ≥99% | |
Adrenomedullin (porcine) | -- | |
Adrenomedullin (1-50), rat | ≥99% | |
Adrenomedullin (16-31), human | ≥99% | |
Adrenomedullin (11-50), rat | -- | |
adrenomedullin 2/intermedin | Moligand™ | |
Adrenomedullin (16-31), human TFA | -- | |
Adrenomedullin (AM) (22-52), human TFA | -- | |
Adrenomedullin (AM) (1-52), human TFA | ≥95% | |
Adrenomedullin Fragment 22-52 human | ≥97% (HPLC) | |
AM-(11-50) (rat) | Moligand™ | |
AM-(20-50) (rat) | Moligand™ | |
[¹²⁵I]AM (rat) | Moligand™ |
8.2 Key Reagents Commonly Used in ADM (Adrenomedullin) Signaling Studies and Detection Workflows
Name | CAS No. | Use Stage | Role in the Workflow | Handling Notes |
IBMX (3-isobutyl-1-methylxanthine) | Signal amplification/control | PDE inhibitor that suppresses cAMP degradation to amplify ADM-induced cAMP signals | Fix final concentration and pre-incubation time; high concentrations are prone to non-specific effects—define an effective window in pilot tests | |
Forskolin | Positive control (AC level) | Directly activates adenylyl cyclase as a cAMP-readout positive control | Run in parallel with ADM to localize “receptor-level” versus “downstream” issues; include vehicle controls and fix stimulation timing | |
H-89 | Pathway inhibition validation | PKA inhibitor used to test whether ADM effects depend on the cAMP/PKA axis | Limited specificity; pair with a second inhibitor or genetic evidence where possible; fix treatment duration | |
ODQ | Downstream NO inhibition | sGC inhibitor used to test the NO–sGC–cGMP axis contribution | Protect from light; combining with L-NAME helps localize steps within the NO pathway | |
Sildenafil | cGMP amplification (as needed) | PDE5 inhibitor that increases cGMP levels to amplify NO–cGMP readouts and support pathway validation | Strongly dependent on baseline NO; use dose gradients and include vehicle controls | |
YC-1 | cGMP positive control (as needed) | sGC activator used to validate cGMP detection systems and downstream accessibility of NO signaling | Pair with ODQ to test specificity; protect from light and fix incubation windows | |
LY294002 | PI3K/AKT inhibition validation | PI3K inhibitor used to test whether ADM-mediated cytoprotection/anti-apoptosis depends on PI3K/AKT | Assess toxicity; use short windows with dose gradients; include vehicle controls | |
MK-2206 | AKT inhibition validation (as needed) | More focused inhibition at the AKT node to strengthen PI3K/AKT evidence chains | Optimize dose and timing; note cell-line dependence | |
U0126 | ERK/MAPK inhibition validation | MEK1/2 inhibitor used to test dependence of ADM-induced ERK signaling and functional readouts | Fix pretreatment time; avoid long exposures that shift baseline cell state | |
PD98059 | ERK/MAPK inhibition validation (as needed) | Alternate MEK inhibitor used to cross-validate ERK-pathway dependence | Use as an orthogonal check to U0126; include vehicle controls | |
DAF-FM diacetate | NO-generation readout | Fluorescent NO probe for detecting ADM-induced NO production | Protect from light; include probe blanks and subtract matrix autofluorescence; standardize loading and incubation | |
Evans blue | Barrier/leakage readout (in vivo/ex vivo) | Vascular leakage tracer dye used to evaluate ADM effects on endothelial barrier integrity | Fix dosing and sampling windows; process samples in the same batch; standardize extraction and quantification | |
FITC-dextran | Barrier permeability readout (in vitro) | Tracer molecule for permeability assays and complementary readouts to TEER | Fix molecular-weight grade and final concentration; include blanks and fluorescence subtraction; fix plate-reader settings | |
BSA (bovine serum albumin) | Carrier/stabilizer and background control | Stabilizes peptides and reduces non-specific adsorption; serves as carrier and blocking component in permeability assays | Matched carrier controls are required; choose low-endotoxin grade and fix lot |
Through CLR–RAMP2/3 receptor complexes, adrenomedullin engages signaling networks that regulate vascular tone, stabilize the endothelial barrier, modulate inflammation, and protect organs, positioning it as a key vasoactive peptide system linking microcirculation, inflammation, and organ function. Because mature ADM is unstable ex vivo, MR-proADM is often a more practical surrogate for biomarker studies. Research on the ADM system should be anchored in receptor specificity and multi-layer evidence chains, and should advance mechanistic and translational exploration only after explicitly separating hemodynamic effects from barrier/immune contributions.
For more related articles, please see below:
[1] Modeling experiments in animal models of pulmonary hypertension